Bladder cancer

Microwave hyperthermia

​​​​Hyperthermia is believed to have a direct and immune-mediated cytotoxic effect on tumour cells and to improve the efficacy of mitomycin C (and other chemotherapy drugs). Intravesical microwave hyperthermia and mitomycin C can be used in the neoadjuvant and adjuvant setting (before or after transurethral resection, respectively). Adjuvant intravesical hyperthermic mitomycin C was not superior to normothermic mitomycin C (with respect to recurrence-free survival at 24 months) in prospective open label randomised trials of patients with intermediate-risk non-muscle-invasive bladder cancer.[136]Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, et al. Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. http://www.ncbi.nlm.nih.gov/pubmed/36435738?tool=bestpractice.com [137]Tan WS, Prendergast A, Ackerman C, et al. Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial. Eur Urol. 2023 Jun;83(6):497-504. https://www.sciencedirect.com/science/article/pii/S0302283822025520?via%3Dihub http://www.ncbi.nlm.nih.gov/pubmed/35999119?tool=bestpractice.com ​